DR P. MARAZZI / SCIENCE PHOTO LIBRARY DR P. MARAZZI / SCIENCE PHOTO LIBRARY
Editorial use only.
Exenatide diabetes drug injectors. Designed to be injected under the skin (subcutaneously), this drug has been available since 2005. It is used to treat type 2 diabetes mellitus, and aids the body in controlling the levels of glucose in the blood. It is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) and is classed as an incretin mimetic (mimicking metabolic hormones that control glucose levels). These injectors contain the Bydureon version of the drug, available since 2012 and injected once per week. This drug is marketed by the AstraZeneca pharmaceutical company.
Model release not required. Property release not required.